Imagine asking people with diabetes how they are feeling instead of relying on blood glucose monitoring and hemoglobin A1C? Yet that is how neurologists have had to collect data to guide their treatment for epilepsy—a condition diagnosed in 1 in 26 people.
Outcomes in newly diagnosed epilepsy have not improved despite availability of many new antiepileptic drugs with differing mechanisms of action, according to a study published in the Journal of the American Medical Association.
Join our webinar to learn about how Eysz plans on transforming epilepsy care and how you can be a founding investor!
The challenges doctors and patients face finding a patient’s correct epilepsy medication and dosage and how it affects patients and their loved ones.
Hear first-hand from a person with epilepsy about the need for better data, why the foundation she heads invested in Eysz, and how people can support the epilepsy community.
How you can invest in Eysz’s digital health solution that has the potential to break the cycle of poor outcomes for epilepsy patients.
People interested in investing in our mission to improve the lives of the 70M people affected by epilepsy or who want to hear more about this exciting technology’s development.
Pediatric neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research program at UCSF Benioff Children’s Hospital, Oakland where she developed the epilepsy program by focusing on excellence in clinical care and research. She stepped back from that role, having secured multiple grants and published more than two dozen peer reviewed publications, to found Eysz. Eysz comes out of her clinical work to help parents, caregivers and physicians quantitate the burdens of epilepsy: seizures and neurocognitive side effects.
Danielle Marano has been involved in the non-profit field for over eleven years. Most recently in her past role as the Executive Director of the Epilepsy Foundation of Nevada. Prior to her arrival, Nevada had no resources or support for patients and families receiving a diagnosis of epilepsy. In 2009 Danielle and a small group of volunteers built a community providing help, education and support for families. Over the next seven years that small group of people turned into thousands served throughout Nevada. Danielle’s work in the epilepsy field is extremely personal to her as she was diagnosed with generalized epilepsy at age thirteen. For over ten years she struggled to gain seizure control. After many failed medications, her team of doctors finally found a combination that worked to control her seizures.
Neil Littman has comprehensive healthcare-specific financial experience in venture philanthropy and investment banking. As a member of the Executive Leadership Team and Director of Business development at the California Institute for Regenerative Medicine (CIRM), Neil managed more than 40 clinical stage stem cell and regenerative medicine therapies totaling over $500 million. Neil was also previously the Vice President of Business Development at Notable Labs, an oncology-focused startup where he led the development of global corporate partnerships through the successful completion of the companies’ $40 million Series B financing. Neil started his career on Wall Street as an investment banker at Deutsche Bank and Thomas Weisel Partners, where he advised emerging growth biotech companies on public and private financings, licensing, M&A and other transactions over $1 billion.